WO2008129994A1 - 含窒素縮合環誘導体、それを含有する医薬組成物及びその医薬用途 - Google Patents

含窒素縮合環誘導体、それを含有する医薬組成物及びその医薬用途 Download PDF

Info

Publication number
WO2008129994A1
WO2008129994A1 PCT/JP2008/057390 JP2008057390W WO2008129994A1 WO 2008129994 A1 WO2008129994 A1 WO 2008129994A1 JP 2008057390 W JP2008057390 W JP 2008057390W WO 2008129994 A1 WO2008129994 A1 WO 2008129994A1
Authority
WO
WIPO (PCT)
Prior art keywords
same
alkylene
pharmaceutical composition
fused ring
prodrug
Prior art date
Application number
PCT/JP2008/057390
Other languages
English (en)
French (fr)
Inventor
Shigeru Yonekubo
Takashi Miyagi
Kohsuke Ohno
Mikie Kambara
Nobuhiko Fushimi
Original Assignee
Kissei Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co., Ltd. filed Critical Kissei Pharmaceutical Co., Ltd.
Priority to CA2680769A priority Critical patent/CA2680769C/en
Priority to KR1020097021440A priority patent/KR101524817B1/ko
Priority to CN2008800125480A priority patent/CN101663302B/zh
Priority to EP08740471.1A priority patent/EP2143724B1/en
Priority to AU2008241853A priority patent/AU2008241853B2/en
Priority to US12/596,313 priority patent/US8217069B2/en
Priority to MX2009010296A priority patent/MX2009010296A/es
Priority to JP2009510849A priority patent/JP5313883B2/ja
Priority to ES08740471.1T priority patent/ES2441196T3/es
Publication of WO2008129994A1 publication Critical patent/WO2008129994A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

【課題】 本発明は、性ホルモン依存性疾患等の予防又は治療剤として有用な化合物を提供する。 【解決手段】 本発明は、GnRH 拮抗作用を有する下記一般式（Ｉ）で表される含窒素縮合環誘導体、プロドラッグ、塩等、それを含有する医薬組成物及びその医薬用途等を提供する。式（Ｉ）中、環Ａ及び環Ｂは、独立して、アリール又はヘテロアリール；ＲＡ及びＲＢは、独立して、ハロゲン、シアノ、アルキル、アルキルスルホニル、−ＯＷ１、−ＳＷ１、−ＣＯＷ２、−ＮＷ３Ｗ４、−ＳＯ２ＮＷ３Ｗ４、アリール等；ＲＣは、Ｈ又はアルキル；Ｅは、酸素原子等；Ｕは、単結合又はアルキレン；Ｘは、Ｙ、−ＣＯ−Ｙ、−ＳＯ２−Ｙ、−Ｓ−（アルキレン）−Ｙ、−Ｏ−（アルキレン）−Ｙ、−ＳＯ２−（アルキレン）−Ｙ等（ＹはＺ又はアミノ等；Ｚは、シクロアルキル、ヘテロシクロアルキル、アリール、ヘテロアリール等）；等である。
PCT/JP2008/057390 2007-04-18 2008-04-16 含窒素縮合環誘導体、それを含有する医薬組成物及びその医薬用途 WO2008129994A1 (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA2680769A CA2680769C (en) 2007-04-18 2008-04-16 Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes
KR1020097021440A KR101524817B1 (ko) 2007-04-18 2008-04-16 질소 함유 축합환 유도체, 그것을 함유하는 의약 조성물 및 그 의약 용도
CN2008800125480A CN101663302B (zh) 2007-04-18 2008-04-16 含氮稠环衍生物、包含所述含氮稠环衍生物的药物组合物及其医药用途
EP08740471.1A EP2143724B1 (en) 2007-04-18 2008-04-16 Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes
AU2008241853A AU2008241853B2 (en) 2007-04-18 2008-04-16 Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes
US12/596,313 US8217069B2 (en) 2007-04-18 2008-04-16 Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes
MX2009010296A MX2009010296A (es) 2007-04-18 2008-04-16 Derivado de anillo fusionado nitrogenado, composicion farmaceutica que lo contiene, y uso del mismo para propositos medicos.
JP2009510849A JP5313883B2 (ja) 2007-04-18 2008-04-16 含窒素縮合環誘導体、それを含有する医薬組成物及びその医薬用途
ES08740471.1T ES2441196T3 (es) 2007-04-18 2008-04-16 Derivado de anillo condensado nitrogenado, composiciones farmacéuticas que lo contienen, y su uso con fines médicos

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-108926 2007-04-18
JP2007108926 2007-04-18

Publications (1)

Publication Number Publication Date
WO2008129994A1 true WO2008129994A1 (ja) 2008-10-30

Family

ID=39875522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057390 WO2008129994A1 (ja) 2007-04-18 2008-04-16 含窒素縮合環誘導体、それを含有する医薬組成物及びその医薬用途

Country Status (11)

Country Link
US (1) US8217069B2 (ja)
EP (1) EP2143724B1 (ja)
JP (1) JP5313883B2 (ja)
KR (1) KR101524817B1 (ja)
CN (1) CN101663302B (ja)
AU (1) AU2008241853B2 (ja)
CA (1) CA2680769C (ja)
ES (1) ES2441196T3 (ja)
MX (1) MX2009010296A (ja)
TW (1) TWI402073B (ja)
WO (1) WO2008129994A1 (ja)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130172328A1 (en) * 2010-06-24 2013-07-04 Crosswing Inc. Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
CN103483268A (zh) * 2013-09-17 2014-01-01 常州大学 一种4，6-二氯-2-甲基-5-硝基嘧啶的制备方法
US8846909B2 (en) 2010-05-24 2014-09-30 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
US8877772B2 (en) 2008-11-25 2014-11-04 University Of Rochester Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors
JP2015199737A (ja) * 2006-08-02 2015-11-12 サイトキネティクス・インコーポレーテッドＣｙｔｏｋｉｎｅｔｉｃｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 特定の化学物質、組成物及び方法
JP2015537053A (ja) * 2012-12-12 2015-12-24 バイエル・クロップサイエンス・アクチェンゲゼルシャフト ビス（３−アミノフェニル）ジスルフィド類及び３−アミノチオール類を製造する方法
US9512118B2 (en) 2011-06-22 2016-12-06 Takeda Pharmaceutical Company Limited Crystal of fused heterocyclic compound
WO2017108282A1 (en) 2015-12-22 2017-06-29 Kancera Ab Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity
CN107074860A (zh) * 2014-09-16 2017-08-18 吉利德科学公司 制备toll样受体调节剂的方法
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
US10508117B2 (en) 2014-09-16 2019-12-17 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US10766899B2 (en) 2006-08-02 2020-09-08 Cytokinetics, Incorporated Methods for preparing substituted imidazo[4,5-b]pyrazines
US11110091B2 (en) 2008-12-09 2021-09-07 Gilead Sciences, Inc. Modulators of toll-like receptors
US11116774B2 (en) 2014-07-11 2021-09-14 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007140903A (ru) * 2005-04-05 2009-05-20 Фармакопия, Инк. (Us) Производные пурина и имидазопиридина для иммуносупрессии
WO2019002473A1 (en) * 2017-06-30 2019-01-03 Antev Limited COMPOSITION FOR THE TREATMENT OF ACUTE URINARY RETENTION
CN115232144B (zh) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 含氮稠环类衍生物、药物组合物及其制备方法和应用
CN115960073A (zh) * 2022-12-02 2023-04-14 中国药科大学 一种n-卤代乙酰基二苯胺衍生物及其制备方法和医药用途
CN117069662A (zh) * 2023-10-17 2023-11-17 峰成医药科技(天津)有限公司 一种4,6-二氯-2-（二氟甲基）嘧啶的合成方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51143696A (en) * 1975-05-28 1976-12-10 Merck & Co Inc 1*33dihydroimidazo *4*55b* pyridinee22one
JPH04305568A (ja) * 1990-09-24 1992-10-28 Neurosearch As ベンズイミダゾール誘導体、その製造方法及びその使用方法
JPH1059942A (ja) 1996-08-13 1998-03-03 Kureha Chem Ind Co Ltd Ｎ−（フェニルスルホニル）ピコリン酸アミド誘導体、その製造方法及び除草剤
JPH11292720A (ja) * 1998-04-13 1999-10-26 Nissan Chem Ind Ltd 縮合イミダゾリノン誘導体を含有する除草剤
WO1999057103A1 (fr) * 1998-04-30 1999-11-11 Nippon Chemiphar Co., Ltd. Derive d'imidazole condense et agent therapeutique permettant de traiter une maladie du foie
JP2003511378A (ja) * 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
WO2005035498A1 (ja) 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. 含窒素二環性化合物の摂食調節剤としての用途
WO2006009734A1 (en) * 2004-06-17 2006-01-26 Wyeth Gonadotropin releasing hormone receptor antagonists
WO2006010594A1 (en) 2004-07-27 2006-02-02 Novartis Ag Inhibitors of hsp90
WO2006036883A2 (en) * 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
WO2006049890A1 (en) * 2004-10-27 2006-05-11 Janssen Pharmaceutica N.V. Pyridine imidazoles and aza-indoles as progesterone receptor modulators
WO2007034817A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK209976A (da) * 1975-05-28 1976-11-29 Merck & Co Inc Fremgangsmade til fremstilling af 3h-1,2,2-triazol(4,5-b)pyridiner
US5200422A (en) 1990-09-24 1993-04-06 Neurosearch A/S Benzimidazole derivatives, their preparation and use
WO1997021704A1 (en) 1995-12-14 1997-06-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU2006251620B8 (en) 2005-05-20 2013-07-18 Elan Pharmaceuticals, Inc. Imidazolone phenylalanine derivatives as VLA-4 antagonists
WO2007035873A1 (en) * 2005-09-21 2007-03-29 Pharmacopeia, Inc. Purinone derivatives for treating neurodegenerative diseases
MX2008008337A (es) * 2005-12-21 2008-09-03 Schering Corp Fenoxipiperidinas y sus analogos utiles como antagonistas de histamina h3.
US7776877B2 (en) * 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51143696A (en) * 1975-05-28 1976-12-10 Merck & Co Inc 1*33dihydroimidazo *4*55b* pyridinee22one
JPH04305568A (ja) * 1990-09-24 1992-10-28 Neurosearch As ベンズイミダゾール誘導体、その製造方法及びその使用方法
JPH1059942A (ja) 1996-08-13 1998-03-03 Kureha Chem Ind Co Ltd Ｎ−（フェニルスルホニル）ピコリン酸アミド誘導体、その製造方法及び除草剤
JPH11292720A (ja) * 1998-04-13 1999-10-26 Nissan Chem Ind Ltd 縮合イミダゾリノン誘導体を含有する除草剤
WO1999057103A1 (fr) * 1998-04-30 1999-11-11 Nippon Chemiphar Co., Ltd. Derive d'imidazole condense et agent therapeutique permettant de traiter une maladie du foie
JP2003511378A (ja) * 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
WO2005035498A1 (ja) 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. 含窒素二環性化合物の摂食調節剤としての用途
WO2006009734A1 (en) * 2004-06-17 2006-01-26 Wyeth Gonadotropin releasing hormone receptor antagonists
WO2006010594A1 (en) 2004-07-27 2006-02-02 Novartis Ag Inhibitors of hsp90
WO2006036883A2 (en) * 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
WO2006049890A1 (en) * 2004-10-27 2006-05-11 Janssen Pharmaceutica N.V. Pyridine imidazoles and aza-indoles as progesterone receptor modulators
WO2007034817A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CLARK R.L. ET AL.: "Synthesis and Analgesic Activity of 1,3-Dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(Substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines", JOURNAL OF MEDICINAL CHEMISTRY, vol. 21, no. 9, 1978, pages 965 - 978, XP001191133 *
HYOJUN SEIRIGAKU: "Standard Physiology", pages: 882 - 891
IYAKUHIN NO KAIHATSU, vol. 7, pages 163 - 198
MARIO BIANCH: "Chimica Therapeitica", EUR. J. MED. CHEM, vol. 16, no. 4, 1981, pages 321 - 326
SANKA TO FUJINKA, OBSTETRICS AND GYNECOLOGY, vol. 71, no. 3, 2004, pages 280 - 285
See also references of EP2143724A4 *
SMALLHEER J.M. ET AL.: "SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 21, 2004, pages 5263 - 5267, XP004580511 *
V.K.AGRAWAL, INDIAN JOURNAL OF CHEMISTRY, vol. 20, May 1981 (1981-05-01), pages 398 - 400

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10766899B2 (en) 2006-08-02 2020-09-08 Cytokinetics, Incorporated Methods for preparing substituted imidazo[4,5-b]pyrazines
JP2015199737A (ja) * 2006-08-02 2015-11-12 サイトキネティクス・インコーポレーテッドＣｙｔｏｋｉｎｅｔｉｃｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 特定の化学物質、組成物及び方法
US9181247B2 (en) 2008-11-25 2015-11-10 The University Of Rochester Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors
US9814704B2 (en) 2008-11-25 2017-11-14 The University Of Rochester Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors
US8877772B2 (en) 2008-11-25 2014-11-04 University Of Rochester Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors
US11110091B2 (en) 2008-12-09 2021-09-07 Gilead Sciences, Inc. Modulators of toll-like receptors
US8846909B2 (en) 2010-05-24 2014-09-30 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
US9226921B2 (en) 2010-06-24 2016-01-05 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors
US20140228320A1 (en) * 2010-06-24 2014-08-14 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
US8940758B2 (en) 2010-06-24 2015-01-27 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US8846713B2 (en) 2010-06-24 2014-09-30 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors
US8563575B2 (en) 2010-06-24 2013-10-22 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US20130172328A1 (en) * 2010-06-24 2013-07-04 Crosswing Inc. Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
US9512118B2 (en) 2011-06-22 2016-12-06 Takeda Pharmaceutical Company Limited Crystal of fused heterocyclic compound
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
JP2015537053A (ja) * 2012-12-12 2015-12-24 バイエル・クロップサイエンス・アクチェンゲゼルシャフト ビス（３−アミノフェニル）ジスルフィド類及び３−アミノチオール類を製造する方法
CN103483268B (zh) * 2013-09-17 2015-10-14 常州大学 一种4,6-二氯-2-甲基-5-硝基嘧啶的制备方法
CN103483268A (zh) * 2013-09-17 2014-01-01 常州大学 一种4，6-二氯-2-甲基-5-硝基嘧啶的制备方法
US11116774B2 (en) 2014-07-11 2021-09-14 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
CN107074860A (zh) * 2014-09-16 2017-08-18 吉利德科学公司 制备toll样受体调节剂的方法
US10508117B2 (en) 2014-09-16 2019-12-17 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US11072615B2 (en) 2014-09-16 2021-07-27 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
CN107074860B (zh) * 2014-09-16 2022-07-15 吉利德科学公司 制备toll样受体调节剂的方法
US11773098B2 (en) 2014-09-16 2023-10-03 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US10654814B2 (en) 2015-12-22 2020-05-19 Kancera Ab Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity
WO2017108282A1 (en) 2015-12-22 2017-06-29 Kancera Ab Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity

Also Published As

Publication number Publication date
CN101663302B (zh) 2013-07-24
TWI402073B (zh) 2013-07-21
EP2143724A4 (en) 2011-09-14
JPWO2008129994A1 (ja) 2010-07-22
US8217069B2 (en) 2012-07-10
JP5313883B2 (ja) 2013-10-09
KR101524817B1 (ko) 2015-06-01
EP2143724A1 (en) 2010-01-13
TW200848052A (en) 2008-12-16
US20100112090A1 (en) 2010-05-06
ES2441196T3 (es) 2014-02-03
CA2680769C (en) 2015-10-13
CN101663302A (zh) 2010-03-03
CA2680769A1 (en) 2008-10-30
MX2009010296A (es) 2009-12-14
EP2143724B1 (en) 2013-12-11
KR20100015567A (ko) 2010-02-12
AU2008241853B2 (en) 2012-11-01
AU2008241853A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
WO2008129994A1 (ja) 含窒素縮合環誘導体、それを含有する医薬組成物及びその医薬用途
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
WO2008011109A3 (en) Substituted pyridone compounds and methods of use
WO2009111653A3 (en) Antiviral therapeutic agents
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
TW200732309A (en) Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
GEP201606560B (en) Macrocyclic derivatives for the treatment of proliferative diseases
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
ZA200707901B (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
TN2011000244A1 (en) Organic compounds
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
WO2008147557A3 (en) Heteroaryl substituted thiazoles and their use as antiviral agents
GEP20156263B (en) Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for production and usage thereof
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
MX2012013274A (es) Novedosos derivados de la pirimidina.
WO2008011110A3 (en) Di-amino-substituted heterocyclic compounds and methods of use
PL1727817T3 (pl) Pochodne azabicyklooktan-3-onu i ich zastosowanie
WO2009105969A8 (zh) 埃坡霉素类似物、其药物组合物、用途及其制备方法
MX2012015100A (es) Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina.
WO2011006935A3 (en) Tetrazole derivatives
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
WO2008133128A1 (ja) 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途
MY150468A (en) Quinolinone derivatives and their pharmaceutical compositions
MX2012004835A (es) Derivados de espirolactama y usos de los mismos.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880012548.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740471

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2680769

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009510849

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6022/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008241853

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/010296

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20097021440

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2008241853

Country of ref document: AU

Date of ref document: 20080416

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12596313

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008740471

Country of ref document: EP